In a subsequent dose-expansion study in patients with heavily pretreated NSCLC, 20% of patients with high CEACAM5 expression (intensity ≥2+ in ≥50% of tumor cells) had a partial response, and almost half of those patients maintained the response for 1 year (14, 15). The gene discussed is CEACAM5; the disease is non-small cell lung carcinoma.